Kifa Therapeutics advances highly selective CNS-kinase inhibitors, starting with a G2019S-LRRK2 therapy for Parkinson’s disease.
Our strategy pairs genetics-based patient selection with validated biomarkers to enable efficient clinical studies and an orphan, accelerated-approval path.
Bluegrass Pharmaceuticals develops advanced Lipid Nanoparticles (LNPs) to enhance vaccine efficacy and enable targeted therapeutic delivery.
Avast Therapeutics is developing first-in-class, non-invasive peptide therapeutics that safely cross the blood-brain barrier to restore mitochondrial function and protect neurons.
This breakthrough approach targets neurodegenerative diseases such as Parkinson’s and Alzheimer’s at their earliest stages, with the potential to halt disease progression and transform brain medicine.
Annoviant is advancing patient outcomes in heart disease by delivering innovative, regenerative cardiovascular devices built on its proprietary TxGuard™ soft-tissue technology.
The platform enables durable, off-the-shelf solutions that address critical unmet needs in heart valve disease and coronary artery bypass grafting—helping patients live healthier lives while reducing long-term healthcare costs.
Nemea Therapeutics is a preclinical-stage company developing oral small molecule inhibitors targeting mitochondrial RNA polymerase (POLRMT) for the treatment of mitochondria-dependent solid tumors.
Pinnacle Financial Partners, a leading Southeastern regional bank headquartered in Nashville, Tennessee, with operations across Tennessee, North Carolina, South Carolina, Virginia, Georgia, Alabama, and beyond, empowers entrepreneurs, growth-stage companies, and venture investors to fuel expansion and achieve long-term success through comprehensive banking, treasury management, lending, and advisory solutions tailored to the innovation economy.
